| Document |
Document Title |
|
WO/2005/070950A1 |
The present invention is a di-steroidal prodrug of ethinyl estradiol according to formula (I)
|
|
WO/2005/054271A1 |
The present invention provides an ecdysteroid derivative in which a fluorescent moiety is attached to an ecdysteroid moiety by derivatisation of a hydroxyl group on the alkyl side chain of the ecdysteroid moiety. The derivative is capabl...
|
|
WO/2005/042422A2 |
An optical fiber, and a method of making such optical fiber, wherein the optical fiber exhibits a beatlength greater than about 0.5 meters, and the fiber is spun to provide a polarization mode dispersion in the spun state of said fiber w...
|
|
WO/2005/037851A1 |
The invention relates to novel crystalline forms of 3-beta-amino 17-methylene androstane-6-alpha 7-beta-diol hydrochloride, referred to as form A, form B and form C, a method for preparing same, the use thereof as a drug, and pharmaceuti...
|
|
WO/2005/030120A2 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula (I) wherein the variables are defined in the specification.
|
|
WO2002042319A9 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.
|
|
WO/2005/026190A1 |
A process for easily producing a cyclic amine in high yield. The process for cyclic amine production comprises aminating, with hydrogen and ammonia, a cyclic ketone in which at least either of the carbon atoms in the &agr -positions with...
|
|
WO/2005/023831A1 |
The invention relates to detection of cholesterol ozonation products that are generated by atherosclerotic plaque material, and to methods of detecting vascular conditions that relate to the accumulation and oxidation of cholesterol.
|
|
WO/2005/009361A2 |
This invention relates to the improved methods of use of Argatroban in heparin-induced thombocytopenia.
|
|
WO/2005/000868A1 |
The invention relates to a process for the synthesis of high purity d-(17&agr )-13-ethyl-17hydroxy-18,19-dinorpregn-4-ene-20-yne-3-one-o
xime (further on norelgestromine) via acetylation of d-norgestrel at position 17, oximation of the...
|
|
WO/2005/000867A1 |
The invention relates to the pure d-(17&agr )-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yne-3-one-
3E-oxime isomer of formula (IA), the pure d-(17&agr )-13-ethyl-17-hydroxy-18,19-dinorpregn-4-ene-20-yne-3-one-3Z
-oxime isomer of fo...
|
|
WO/2004/101595A1 |
Compounds and methods for modulating mesenchymal cell function, for instance smooth muscle and fibroblast proliferation or cytokine expression, and for treating conditions associated with mesenchymal cell function, for instance airway hy...
|
|
WO/2004/085457A2 |
There is provided a compound of Formula (I) wherein (I) R1 is a selected from (i) an alkyloxyalkyl group (ii) a nitrile group, and wherein R2 is capable of forming a hydrogen bond (iii) alkylaryl group, wherein the aryl group is substitu...
|
|
WO/2004/085459A1 |
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of -OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide gr...
|
|
WO/2004/074309A1 |
The invention relates to D-homoestra-1, 3, 5 (10)-trien-3-yl 2-substituted sulfamates of general formula (I), wherein R3 is C1-C5 alkyl or a C1-C5 alkyloxy group and to the use thereof for producing a drug for curing tumoral diseases whi...
|
|
WO/2004/074308A1 |
The invention relates to the use of compounds of a general formula (I), wherein R2, R14 to R17 and X groups have the following significance: R2 is C1-C5-Alkyl, C1-C5-Alkoxy or a -O-CNFmHo rest, wherein n=1,2,3,4,5 or 6, m>1 and m+o=2n+1,...
|
|
WO/2004/074307A1 |
The invention relates to the use of 2-substituted estra-1,3,5(10)-triene-3-yl sulfamates of general formula I, in addition to their pharmaceutically acceptable salts for producing a medicament. Said compounds have an anti-tumour action.
|
|
WO/2004/065405A1 |
The invention relates to a method of obtaining 17$g(a)-acetoxy-11$g(b)-(4-N,N-dimethylaminophenyl)-19-norpr
egna-4,9-diene-3,20-dione. The inventive method consists in: (a) forming crystals of the isopropanol hemisolvate of 17$g(a)-aceto...
|
|
WO/2004/052913A1 |
The present invention relates to a digoxin-labelled glycan which comprises a digoxin moiety having a glycosidic chain attached to a steroid moiety, and a glycan moiety and methods of their production. The invention also relates to the us...
|
|
WO2004011663A9 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
|
WO/2004/014935A1 |
The invention relates to novel compounds of general formula (I), to the production thereof and to pharmaceutical preparations containing these compounds. The inventive compounds are preferably used in female fertility testing and hormone...
|
|
WO2003070745B1 |
Carbonates and carbamates of the formula and related steroid carbonates and carbamates are disclosed. The compounds are useful for treating rhinitis and asthma, particularly by inhalation, and for treating inflammation, particularly by l...
|
|
WO/2004/013086A1 |
Diamine compounds, which in particular are useful as precursors for the production of liquid crystal alignment layers, represented by general formula (I), wherein A1 represents an organic group of 1 to 40 carbon atoms; A2 represents a hy...
|
|
WO/2004/012686A2 |
The invention describes nitrosated and/or nitrosylated ursodeoxycholic acid compounds, or an amide or sulfate conjugate thereof, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/...
|
|
WO/2004/011528A1 |
A liquid crystal alignment agent capable of not only exhibiting excellent alignment characteristics but also forming a liquid crystal alignment layer film with which the time from cancellation of voltage application to afterimage erasure...
|
|
WO/2004/007522A2 |
The invention concerns compounds capable of being fixed on hormone receptors and having a nitrogen monoxide donor group, their use for preventing premature births, increasing cervical dilatation, for use in hormone substitution therapy a...
|
|
WO/2004/000802A2 |
Disclosed are scaffolded maleimide clusters, methods of making said clusters and use of said clusters as templates for multivalent peptide assembly. Multiple maleimide functionalities were introduced onto a scaffold molecule by the react...
|
|
WO/2004/001369A2 |
The present invention provides a convenient process for the preparation of S-fluoromethyl 6a, 9a-difluoro-11b-hydroxy-16a-methyl-17a-propionyloxy-3-oxoand
rosta-1, 4-diene-17b-carbothioate, a compound of formula (1), comprising(a) treati...
|
|
WO/2004/000869A1 |
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering ...
|
|
WO/2003/104253A2 |
The invention relates to novel 9$g(a)-substituted estratrienes of general formula (I) - wherein R3, R7, R7', R13, R16, R17 and R17' have the designations cited in the description, and R9 represents a linear-chain or branched-chain, optio...
|
|
WO/2003/095471A2 |
Use of compounds and their salts of formula (I), as reported in the description, in the preparation of drugs for the treatment of acute dysfunctions of portal and hepatic venous circulation.
|
|
WO/2003/090721A2 |
The invention relates to a method for producing crystals from active ingredients in medicaments, the average particle size thereof lying within a given range and the maximum particle size thereof not exceeding a given value. During cryst...
|
|
WO/2003/090714A1 |
Disclosed is a method for producing crystals, the average particle size of which lies within a predefined range while the maximum particle size does not exceed a given value. According to the inventive method, an oversaturated solution o...
|
|
WO/2003/091272A1 |
The invention relates to a method for producing steroid crystals, whose average particle size lies in a predetermined range and whose maximum particle size does not exceed a predetermined value. According to the invention, a supersaturat...
|
|
WO/2003/089449A2 |
The invention relates to sterol derivatives of formula (I) and to a method for the production of said compounds, a medicament using one of said compounds and a pharmaceutical composition comprising said medicament.
|
|
WO/2003/087121A1 |
Novel compounds comprising a steroid backbone coupled to a branched polyamine according to formula (I); are provided. The compounds show antimicrobial activity and may be used in the treatment and prevention of infections, in particular ...
|
|
WO/2003/086303A2 |
The invention relates to compounds of formula (I) in which n, R3, R4, R5, R6, R10, R13, R17, X, Y, and Z are defined above. The invention also relates to pharmaceutical compositions each containing an effective amount of one or more comp...
|
|
WO/2003/080642A1 |
The invention relates to novel 19-nor-17$g(a)-pregna-1,3,5(10)-trien-17$g(b)-ols with a 21,16a lactone ring having a long-chain substituent in the 11$g(b) position of general formula (II), wherein R11 represents a long-chain alkyl radica...
|
|
WO/2003/072109A1 |
The invention relates to the use of mono-sulfamate prodrugs of estriol, such as estriol-3-sulfamate, for the treatment of autoimmune diseases, such as multiple sclerosis (MS).
|
|
WO/2003/070194A2 |
Amino acid corticosteroid esters which may function as pro-drugs, and formulations of the amino acid corticosteroid esters with a second active ingredient such as formoterol are disclosed. Composition of the invention include amino acid ...
|
|
WO/2003/068736A2 |
Disclosed herein are mixed steroidal tetraoxanes having the following structural Formula (I), wherein n is 0, 1, 2, or 3; R is H; ethanoyl, propanoyl, or benzoyl; R1 is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or ethyl; R3 is H, ...
|
|
WO/2003/064443A2 |
Nitrooxy derivatives of steroidal compounds of general formula (I) B− X1 − NO2 or esters or salts thereof, wherein: B is a steroidal radical, X1 is a bivalent linking group comprising an aromatic or heterocyclic ring.
|
|
WO/2003/053365A2 |
Disclosed are aqueous and nonaqueous solution formulations containing agents that are useful for treating cancer.
|
|
WO/2003/053992A2 |
This invention describes a safe method for the production of sulfamoyl chloride from chlorosulfonyl isocyanate and formic acid in the presence of a amide catalyst, taming the hazardous nature of this reaction by circumventing heat accumu...
|
|
WO/2003/047549A2 |
The present invention provides a delivery vehicle for a therapeutic agent comprising a modified lipid and a therapeutic agent; wherein the modified lipid comprises a lipid and a delivery, targeting or stabilising moiety (DTS moiety); whe...
|
|
WO/2003/045972A1 |
The invention relates to 17$g(a)-alkyl-17$g(b)-oxy-estra-1,3,5(10)-trienes having an anti-oestrogen action, of general formula (I). The invention also relates to 17-oxo-estra-1,3,5(10)-trienes and 17$g(b)-hydroxy-estra-1,3,5(10)-trienes ...
|
|
WO/2003/039480A2 |
A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I). Also disclosed are methods, kits, combinations, and compositions for treating a...
|
|
WO/2003/038523A2 |
Mixed carbocycle derivatives containing at least two carbocycles per molecule from the group of anthracenes, adamantanes and steroids with functionalized carbon chains are synthesized and used as modifiers of resist properties and especi...
|
|
WO2002094942A9 |
The disclosed invention pertains to technology of fabricating and purifying synthetic dyes and may be used in various areas of industry and national economy, particularly in fabrication of materials for polarizing coatings of various pur...
|
|
WO/2003/027132A2 |
A highly pure 17β-N-tert-butylcarbamoyl-3-one steroid compound of formula (I) is prepared in a high yield under a mild condition, by reacting a 17β-carboxy-3-one steroid compound with a pivaloyl halide to obtain a pivaloyl acid anhydri...
|
